Cargando…

The Association Between Urinary Tract Infection and Overactive Bladder Treatment

Background: Overactive bladder (OAB) syndrome is defined as urinary urgency, with or without urge incontinence in the absence of an underlying pathological or metabolic cause. Treatment for OAB involves anti-muscarinic agents and beta 3-adrenoceptor agonists. As a previous study showed that treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liao, Kuang-Ming, Lio, Ka-Lok, Chou, Yu-Ju, Kuo, Chen-Chun, Chen, Chung-Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822154/ https://www.ncbi.nlm.nih.gov/pubmed/35145406 http://dx.doi.org/10.3389/fphar.2021.803970

Ejemplares similares

Recurrent urinary tract infection in women and overactive bladder – Is there a relationship?
por: Ke, Qian-Sheng, et al.
Publicado: (2020)

Urinary Tract Infection in Overactive Bladder: An Update on Pathophysiological Mechanisms
por: Mansfield, Kylie J., et al.
Publicado: (2022)

NMDAR in bladder smooth muscle is not a pharmacotherapy target for overactive bladder in mice
por: Xie, Xiang, et al.
Publicado: (2021)

Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder
por: Gong, Qin-Qin, et al.
Publicado: (2020)

Intravesical OnabotulinumtoxinA Injection for Overactive Bladder Patients with Frailty, Medical Comorbidities or Prior Lower Urinary Tract Surgery
por: Liao, Chun-Hou, et al.
Publicado: (2016)

Urodynamic characteristics of lower urinary tract of patients with idiopathic overactive bladder
por: Dekhtiar, Yuriy M., et al.
Publicado: (2019)

Urinary biomarkers of overactive bladder
por: Tian, Xiao-Jun, et al.
Publicado: (2019)

Urinary beta 3-adrenoceptor as a diagnostic biomarker for overactive bladder in women
por: Liang, Ching-Chung, et al.
Publicado: (2023)

Weak association between arterial hypertension and overactive bladder baseline symptoms and treatment responses
por: Michel, Martin C., et al.
Publicado: (2022)

Urinary Microbiome and Psychological Factors in Women with Overactive Bladder
por: Wu, Peng, et al.
Publicado: (2017)

The Prevalence of Lower Urinary Tract Symptoms and Overactive Bladder in South Korea: A Cross-Sectional, Population-Based Study
por: Kim, Myung Ki, et al.
Publicado: (2022)

Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder
por: Lee, Seung Hwan, et al.
Publicado: (2014)

Fesoterodine for the treatment of urinary incontinence and overactive bladder
por: Ellsworth, Pamela
Publicado: (2009)

Socioeconomic Costs of Overactive Bladder and Stress Urinary Incontinence in Korea
por: Sung, Wooseuk, et al.
Publicado: (2012)

A Novel Intravesical Dextrose Injection Improves Lower Urinary Tract Symptoms on Interstitial Cystitis/Bladder Pain Syndrome
por: Chen, Chin-Li, et al.
Publicado: (2021)

Association of diabetes, hypertension, and their combination with basal symptoms and treatment responses in overactive bladder patients
por: Müderrisoglu, A. Elif, et al.
Publicado: (2023)

Prevalence and bother of lower urinary tract symptoms and overactive bladder in Poland, an Eastern European Study
por: Przydacz, Mikolaj, et al.
Publicado: (2020)

Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan—A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)
por: Wang, Chung-Cheng, et al.
Publicado: (2021)

Levofloxacin Versus Ciprofloxacin in the Treatment of Urinary Tract Infections: Evidence-Based Analysis
por: Cao, Dehong, et al.
Publicado: (2021)

Daidzein is the in vivo active compound of Puerariae Lobatae Radix water extract for muscarinic receptor-3 inhibition against overactive bladder
por: Qiang, Yining, et al.
Publicado: (2022)

Urinary ATP May Be a Dynamic Biomarker of Detrusor Overactivity in Women with Overactive Bladder Syndrome
por: Silva-Ramos, Miguel, et al.
Publicado: (2013)

Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements
por: Javan Balegh Marand, Aida, et al.
Publicado: (2023)

The use of ultrasound-estimated bladder weight in diagnosing bladder outlet obstruction and detrusor overactivity in men with lower urinary tract symptoms
por: Housami, Fadi, et al.
Publicado: (2009)

Correlation between overactive bladder symptom score and neuropsychological parameters in Alzheimer’s disease patients with lower urinary tract symptom
por: Jung, Ha Bum, et al.
Publicado: (2017)

Practical Aspects of Botulinum Toxin-A Treatment in Patients With Overactive Bladder Syndrome
por: Liao, Chun-Hou, et al.
Publicado: (2015)

Hengli(®) Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
por: Liao, Limin, et al.
Publicado: (2022)

Toileting behaviors, urinary cues, overactive bladder, and urinary incontinence in older women
por: O’Connell, Kathleen A., et al.
Publicado: (2022)

Effects of Tamsulosin on Urinary Bladder Function and Neuronal Activity in the Voiding Centers of Rats with Cyclophosphamide-induced Overactive Bladder
por: Kim, Sung-Eun, et al.
Publicado: (2012)

Prevalence, Bother and Treatment Behavior Related to Lower Urinary Tract Symptoms and Overactive Bladder among Cardiology Patients
por: Przydacz, Mikolaj, et al.
Publicado: (2020)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Individualizing medical treatment of overactive bladder
por: Kuo, Hann-Chorng
Publicado: (2018)

Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of upper urinary tract and urinary bladder
por: He, Hong-Lin, et al.
Publicado: (2023)

Solifenacin/Mirabegron Induces an Acute Compliance Increase in the Filling Phase of the Capacity-Reduced Urinary Bladder: A Pressure-Volume Analysis in Rats
por: Peng, Hsien-Yu, et al.
Publicado: (2021)

Overactive bladder with urodynamic study-induced bladder pain: An overactive bladder subtype with symptoms similar to those of interstitial cystitis/painful bladder syndrome
por: Mu, Hsueh-Yu, et al.
Publicado: (2023)

Urinary tract infection in the neurogenic bladder
por: Vigil, Humberto R., et al.
Publicado: (2016)

Botulinum toxin A for the Treatment of Overactive Bladder
por: Hsieh, Po-Fan, et al.
Publicado: (2016)

Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry
por: Hsiao, Sheng-Mou, et al.
Publicado: (2019)

Undertreatment of overactive bladder among men with lower urinary tract symptoms in the United States: A retrospective observational study
por: Burnett, Arthur L., et al.
Publicado: (2020)

Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder
por: Matsuo, Tomohiro, et al.
Publicado: (2019)

Lower Urinary Tract Symptoms and Overactive Bladder in a Large Cohort of Older Poles—A Representative Tele-Survey
por: Przydacz, Mikolaj, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v29snk9dkruu5alvn753gtf9b9